Alector Inc (NAS:ALEC)
$ 1.78 -0.04 (-2.2%) Market Cap: 174.32 Mil Enterprise Value: -244.33 Mil PE Ratio: 0 PB Ratio: 1.47 GF Score: 50/100

Alector Inc at Citi BioPharma Conference (Virtual)- Panel: What's Next for Neurodegenerative Diseases Transcript

Sep 08, 2021 / 03:35PM GMT
Release Date Price: $21.65 (-18.97%)
Neena Marie Bitritto;Garg
Citigroup Inc., Research Division - VP & Analyst

So good morning, everybody, and thank you for attending Citi's 16th Annual Biopharma Conference. I'm Neena Bitritto-Garg, I'm one of the biotech analysts here at Citi, if you don't already know me.

For our next session, I'm really pleased to be joined this morning by the CEOs of 3 companies working in the neurodegenerative disease space, including Arnon Rosenthal, from Alector; Bruce Goldsmith from Passage Bio; and Gene Kinney from Prothena. So we're going to cover some emerging topics kind of on the outlook neurodegenerative disease, R&D at a high level and then some indication and company-specific questions as well.

And if anybody listening to the webcast has questions as we go through the discussion you can feel free to e-mail me directly or you can submit questions through the online portal and they'll come to me and I'll try and incorporate them as time permits. So I just want to start off by turning it over to all of you to kind of give some opening remarks. Maybe we can go

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot